Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2017-03-16 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific operational update: the initiation of a Phase 3 Extension Study (PLEO-CMT-FU) for a drug candidate (PXT3003). It details clinical trial progress, expected timelines for results and regulatory submissions, and provides background on the disease and the company's platform. This type of announcement, focusing on clinical trial milestones and operational progress rather than comprehensive financial results (like 10-K or ER) or management changes (MANG), is best classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, nor a specific financial report, and it is not a transcript, presentation, or factsheet, the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for significant corporate news releases that don't fit the other specific categories, although 'LTR' (Legal Proceedings Report) or 'CAP' (Capital/Financing Update) are sometimes used for clinical trial news, RNS serves as the best fit for a general press release about clinical progress.
2017-03-16 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific corporate event: the initiation of the Phase 3 extension clinical study (PLEO-CMT-FU) for the drug PXT3003. It details clinical trial progress, expected timelines for results and regulatory submissions, and provides general company information. This format—a formal announcement of a significant operational/clinical update released to the public and media—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release detailing operational progress (clinical trial initiation/update) rather than just financial results highlights (ER) or a miscellaneous regulatory filing (RNS), and given the options, it most closely aligns with a general corporate announcement. However, in the context of financial reporting databases, press releases detailing operational milestones (like clinical trial progress) often fall under the general Regulatory Filings (RNS) category if they don't fit a more specific financial report type (like 10-K, IR, ER). Since it is not a full report (10-K, IR) and not explicitly a management discussion (MDA) or earnings release (ER), RNS is the most appropriate fallback for a press release detailing operational news.
2017-03-16 French
Pharnext gibt Forschungs- und Entwicklungsvereinbarung mit Galapagos zum Aufbau einer neuen Pipeline synergistischer Wirkstoffkombinationen bekannt
Regulatory Filings Classification · 1% confidence The document is a press release dated March 9, 2017, announcing a Research and Development agreement between Pharnext and Galapagos regarding synergistic drug combinations. It uses terms like "DGAP-News," "Corporate News/Finanznachricht," and provides contact details for investor relations and media. This format is characteristic of a general corporate announcement or news release regarding a significant business event (a partnership/collaboration), rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general corporate announcement about a strategic development that doesn't fit the highly specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is the general regulatory announcement/news category, RNS, which serves as a fallback for such disclosures. However, given the content is a detailed announcement of a strategic business development (R&D agreement), it is more specific than a generic 'Regulatory Filing' (RNS). In many databases, major corporate partnership announcements that are not explicitly earnings or financing events fall under a general news or corporate action category. Since there is no specific 'Partnership Announcement' code, and it is not a formal financial report, RNS is the best fit among the provided options for a general corporate news release distributed via a service like DGAP/EQS.
2017-03-09 German
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release announcing a research and development (R&D) agreement between Pharnext and Galapagos regarding synergistic drug combinations. It details the nature of the collaboration, the technology involved (PLEOTHERAPY™), and includes quotes from the CEOs of both companies. This type of announcement, detailing strategic business development, partnership formation, or significant operational updates outside of routine financial reporting (like earnings or annual reports), typically falls under a general regulatory announcement or a specific business development category. Since there is no specific category for 'R&D Agreement Announcement' and it is not a formal financial filing (like 10-K, ER, or IR), it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the terms implied immediate funding, but here it is purely R&D collaboration. Given the options, RNS serves as the best general regulatory announcement fallback for press releases detailing strategic partnerships.
2017-03-09 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a significant business event: a Research and Development (R&D) partnership between Pharnext and Galapagos. This type of announcement, detailing strategic collaborations, pipeline updates, and management commentary, is characteristic of a general corporate announcement rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a press release announcing a strategic business development, it fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS), or potentially a general corporate announcement if one existed. Given the provided definitions, RNS serves as the best fit for a general, non-financial-specific corporate announcement released to the public/market.
2017-03-09 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that Pharnext's management team will be presenting at the 'BIO CEO & Investor Conference 2017'. It details the date, time, and location of the presentation and provides contact information for scheduling meetings. This type of announcement, which publicizes the company's participation in an investor-focused event where presentations will be given, aligns best with the 'Investor Presentation' category, as it is directly related to presenting company information to investors, even if the presentation itself is scheduled for a future date. It is not a full report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS). It is specifically about an upcoming investor presentation event.
2017-02-07 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.